Have a feature idea you'd love to see implemented?
Let us know!
QNCX Quince Therapeutics Inc
Price (delayed)
$2.08
Market cap
$91.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.24
Enterprise value
$104.2M
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence
Highlights
The quick ratio has plunged by 76% YoY but it has soared by 53% from the previous quarter
The net income has shrunk by 90% YoY
The EPS has dropped by 63% year-on-year
Key stats
What are the main financial stats of QNCX
Market
Valuations
Earnings
Shares outstanding
44M
Market cap
$91.52M
Enterprise value
$104.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
2
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$53.13M
EBITDA
-$52.66M
Free cash flow
-$30.58M
Per share
Balance sheet
Liquidity
EPS
-$1.24
Free cash flow per share
-$0.71
Book value per share
$1.04
Revenue per share
$0
TBVPS
$1.44
Total assets
$126.52M
Total liabilities
$81.59M
Debt
$15.35M
Equity
$44.93M
Working capital
$46.29M
Debt to equity
0.34
Current ratio
9.53
Quick ratio
8.82
Net debt/EBITDA
-0.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-36.2%
Return on equity
-84.8%
Return on invested capital
-78.6%
Return on capital employed
-43.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
QNCX stock price
How has the Quince Therapeutics stock price performed over time
Intraday
13.04%
1 week
9.47%
1 month
154.75%
1 year
138.83%
YTD
98.1%
QTD
167.97%
Financial performance
How have Quince Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.53M
Net income
-$53.26M
Gross margin
N/A
Net margin
N/A
The net income has shrunk by 90% YoY
QNCX's operating income has dropped by 66% year-on-year and by 5% since the previous quarter
Growth
What is Quince Therapeutics's growth rate over time
Valuation
What is Quince Therapeutics stock price valuation
P/E
N/A
P/B
2
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 63% year-on-year
QNCX's P/B is 55% below its 5-year quarterly average of 4.4
The equity has decreased by 46% YoY and by 4.3% QoQ
Efficiency
How efficient is Quince Therapeutics business performance
The ROE has shrunk by 173% YoY and by 16% QoQ
The ROIC has dropped by 53% year-on-year but it has increased by 2.6% since the previous quarter
Quince Therapeutics's ROA has decreased by 20% YoY but it has increased by 7% from the previous quarter
Dividends
What is QNCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for QNCX.
Financial health
How did Quince Therapeutics financials performed over time
QNCX's total assets is 55% greater than its total liabilities
The quick ratio has plunged by 76% YoY but it has soared by 53% from the previous quarter
The current ratio has plunged by 75% YoY but it has soared by 55% from the previous quarter
The debt is 66% lower than the equity
The equity has decreased by 46% YoY and by 4.3% QoQ
QNCX's debt to equity is up by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.